News Search Results
Aug 27, 2025, 01:32 ET Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer
webcast will be made available on our website shortly after the presentation. About Oncoinvent Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide
More news about: Oncoinvent AS
Aug 26, 2025, 18:00 ET WesternU receives 150-acre land gift to expand health care education in Oregon
Calif. and Lebanon, Ore., is an independent nonprofit health professions university, conferring degrees in biotechnology and pharmaceutical sciences, dental medicine, medical sciences, nursing, optometry, osteopathic medicine, pharmacy, physical therapy, physician
More news about: Western University of Health Sciences
Aug 26, 2025, 17:46 ET Global Digital Biomarkers Market Anticipating Remarkable Growth at a CAGR of ~17% by 2032 | DelveInsight
healthcare, digital biomarkers are emerging as a critical component in personalized medicine and remote patient monitoring. Pharmaceutical and biotechnology companies are actively integrating digital biomarkers into clinical trials to enhance patient stratification, monitor treatment adherence,
More news about: DelveInsight Business Research, LLP
Aug 26, 2025, 14:35 ET CAR-T Cell Therapy Market to Reach USD 11,142.53 million by 2032, growing at a CAGR of 12.3%: Credence Research
refractory cases, thus fueling market growth. Advancements in CAR-T Technology Continuous progress in genetic engineering and biotechnology has significantly enhanced the safety and efficacy of CAR-T therapies. Innovations such as next-generation CAR designs, improved cell expansion
More news about: Credence Research Inc.
Aug 26, 2025, 12:35 ET Activation Capital Names Michael Steele as President and CEO
entrepreneurs, and partners to bring innovation to life, right here in the Commonwealth." About Virginia Biotechnology Research Partnership Authority The Virginia Biotechnology Research Partnership Authority ("Authority") is a political subdivision of the Commonwealth of Virginia
More news about: Activation Capital
Aug 26, 2025, 12:02 ET Cerecin Joins NIHR HealthTech Research Centre in Brain Health as an Industry Partner
future innovations, both independently and in concert with other industry leaders. About Cerecin Cerecin is a US-based clinical-stage biotechnology company focused on developing drugs that target the metabolic basis of neurological diseases. Cerecin's development programs leverage its extensive
More news about: Cerecin, Inc
Aug 26, 2025, 10:06 ET Hydrosome Labs Study Links Ultrafine Bubble Water to Better Gut Health and Lower Inflammation
Hydrosome Labs, a Chicago-based biotechnology company pioneering ultrafine bubble (UFB) technology, announced groundbreaking preclinical results showing that its UFB-treated water can beneficially
More news about: Hydrosome Labs
Aug 26, 2025, 10:00 ET High-Precision Base Editing Clinical Treatment for Sickle Cell Disease -- CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient
(Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced the successful treatment of the
More news about: CorrectSequence Therapeutics
Aug 26, 2025, 09:00 ET Debut Raises $20M to Fast-track AI Ingredient Discovery in Skin Longevity and Grow its Formulation Business in the US and Asia
among others. Debut The leader in biotech beauty Debut is building the future of beauty with cutting-edge AI and biotechnology, creating high-performing, innovative ingredients and formulations that propel the industry forward. The company specializes in scientifically-discovered,
More news about: Debut Biotechnology
Aug 26, 2025, 09:00 ET iNtRON Bio, files Two Patent Applications for IMPA™ Platform-Based Gene Editing Technology
https://www.prnewswire.com/news-releases/intron-bio-files-two-patent-applications-for-impa-platform-based-gene-editing-technology-302538358.html SOURCE iNtRON Biotechnology, Inc.
More news about: iNtRON Biotechnology, Inc.
Aug 26, 2025, 08:38 ET 6th Annual #GetOnBoard Week: How Women Lead Honors Visionary Impact and Advocacy in 2025
portfolios in the country—serving on more than 35 public company boards and 14 private company boards, including Costco Wholesale Corporation, Sana Biotechnology, and DocuSign, where she currently serves as Board Chair. At Costco, she has helped guide a board that continues to stand firm in its values,
More news about: How Women Lead
Aug 26, 2025, 08:31 ET MetaVia to Present at Upcoming Investor and Industry Conferences
Aug. 26, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced its participation in upcoming investor and industry conferences.
More news about: MetaVia Inc.
Aug 26, 2025, 08:30 ET p-Tau 205 and p-Tau 212: Emerging Biomarkers for Alzheimer's Disease Research, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 26, 2025, 08:30 ET Advancing ADC Design Through Site-Specific Conjugation and Stable Linkers, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 26, 2025, 08:30 ET ADCs in Oncology Trials: Practical Strategies for Clinical Development Success, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 26, 2025, 08:05 ET Rigel to Participate in Upcoming September Investor Conferences
Aug. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president
More news about: Rigel Pharmaceuticals, Inc.
Aug 26, 2025, 08:05 ET INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults
MEETING, Pa., Aug. 26, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Aug 26, 2025, 08:00 ET Corteva Appoints Jennifer Johnson Chief Legal Officer
represented pharmaceutical and biotechnology companies in patent litigation. Johnson serves on the Advisory Board of the New York Botanical Garden. She previously served on the Board of Directors of the California Life Sciences Association and has taught biotechnology law at the University
More news about: Corteva, Inc.
Aug 26, 2025, 08:00 ET Theradaptive Treats First Patient in RESTORE Feasibility Study Evaluating OsteoAdapt™ DE in Dental Procedures
Theradaptive, Inc., a clinical-stage biotechnology company pioneering targeted protein therapeutics for tissue regeneration, today announced that the first patient has been successfully treated in
More news about: Theradaptive
Aug 26, 2025, 07:30 ET Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September
Aug. 26, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune response detection and diagnostics, today announced it has signed a Research Services Agreement ("RSA") with Emory
More news about: Virax BioLabs Group Limited
Aug 26, 2025, 07:00 ET Nanoscope Announces Groundbreaking 3-Year REMAIN Trial Data for Patients with Retinitis Pigmentosa at 2025 Euretina Congress and Retina Society Annual Scientific Meeting
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Aug 26, 2025, 06:45 ET Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Aug 26, 2025, 04:00 ET High-Precision Base Editing Clinical Treatment for Sickle Cell Disease -- CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient
Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced the successful treatment of the
More news about: CorrectSequence Therapeutics
Aug 26, 2025, 02:00 ET High-Precision Base Editing Clinical Treatment for Sickle Cell Disease -- CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient
Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced the successful treatment of the
More news about: CorrectSequence Therapeutics
Aug 26, 2025, 01:36 ET CAPR Stockholders with Large Losses Should Contact Robbins LLP Before the Lead Plaintiff Deadline for Information About Leading the Capricor Therapeutics, Inc. Class Action Lawsuit
securities between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating
More news about: Robbins LLP